Alternatives to Vita Bella

Flat at every dose - $99 semaglutide, $134 tirzepatide, all fifty states - which makes the annual math trivial. The site never names its operating company.

Compounded semaglutide at $79 a month and tirzepatide at $119, month to month, with no dose-based increase and — checked in its own checkout data rather than taken on trust — a renewal price identical to the joining price. That last part is rarer than it should be. Two things the homepage will not tell you. The $49 and $99 it advertises are the twelve-month totals divided by twelve, not a monthly rate you can start on, and the countdown beside them is not a real deadline: it read August 15th and then August 20th within the same hour. The larger caveat is corporate. NextMeds is operated by Trinity HealthCare Supply, LLC, which also runs Lean Meds, altRx and Trinity Meds, and that operator holds an open FDA warning letter.

For a working mother the appeal here is logistics as much as money: a fully online intake with no video call to schedule, all 50 states, and one flat charge per month that covers the visit, the plan, the medication and shipping — held at the same price whatever dose you end up on. Month to month that is $79 for compounded semaglutide and $109 for compounded tirzepatide; the $69 the homepage headlines under a countdown timer is the twelve-month tier, and $95 is its tirzepatide equivalent. Flat-by-dose is the part that actually protects a budget, because dose-priced providers routinely double between a starting and a maintenance dose. Two things to weigh against that. The off-ramp is narrow: subscriptions auto-renew, canceling means emailing care@leanmeds.com at least 48 hours before the processing date, and the order stops being refundable the moment you submit the medical intake. And the operator named throughout its own Terms — Trinity HealthCare Supply, LLC — is the company FDA wrote to on 8 June 2026 under its other brand, altRx, for labeling compounded vials with its own name when it was not the compounder and for calling compounded GLP-1s 'clinically proven.' That letter concerns altrx.com, not this site, but it is the same legal entity at the same Miami suite, and no pharmacy or clinician is named here either.

FDA warning letter #721472 (Feb. 2026), which names newself.com. A flat, dose-independent price for both molecules — $99.97/mo semaglutide, $144.49/mo tirzepatide, same price at every dose — nationwide, though it requires 3 months upfront.

$99 semaglutide, $149 tirzepatide, flat at every dose, all 50 states. Renewal prices match advertised prices in the checkout data, so the no-price-rise claim holds. A plan month is four weeks; the '12-month' plan at $999 is 48 weeks. Same operator as Lean Meds, altRx and NextMeds — one company, four storefronts — and that operator holds FDA letter 728236, still open.

Mondae is built for someone who wants the decisions made up front and then left alone. Price, plan length and — unusually — which of six named compounding pharmacies fills the prescription are all settled before intake, the questionnaire is asynchronous with no video call to book, and it serves all 50 states. The rate is $115 a month for compounded semaglutide and $145 for compounded tirzepatide, with no membership fee stacked on top and no increase as you titrate: 'your dose may increase, but your price is fixed.' For a working parent that predictability is the whole point, because a dose-priced plan can quietly double between a starting and a maintenance dose. The pharmacy disclosure is the standout — Boudreaux, Rush, Hallandale, Greenwich, Align and VialsRx, named and selectable, where most of this category names none — with the honest caveat that Mondae itself flags: each ships to different states and formulations 'may contain additional additives.' Both prices were verified from a rendered page rather than a marketing card, because the raw HTML ships a '$NNN' placeholder, and they agree with the homepage card and the page's own structured data. What is absent is routine: no named clinician behind the contracted Bask Telehealth network, no labs, no refunds once medication is dispensed, and nothing addressing postpartum recovery, breastfeeding or PCOS.

A named-Medical-Director program licensed in all 50 states, from $99/mo semaglutide and $183/mo tirzepatide, with no membership required — but it carries a 2025 FDA warning letter over how it described its compounded medication, and both prices are 'From' starting prices rather than a guaranteed working-dose rate.

Both prices came down since our last check — read live on 2026-08-26 the product cards say compounded semaglutide from $99 a month and tirzepatide from $199, against $149 and $224 in mid-August, with microdose versions at $119 and $139 beside them. Still "from", and Medro is unusually candid about what that means: its own FAQ says starting-at pricing "reflects the lowest typical option" and that final cost varies by medication, dose, supply duration, partner pricing, availability and eligibility, while a footnote under the cards calls the pricing "illustrative". Two other things this record used to get wrong. The site does name its operating entity, Medro Health Technologies, Inc., in the Refund Policy, along with its clinical partner Arora Health & Aesthetics in Seattle and its pharmacy partner The Pharmacy Hub in Miami. And it does publish a cancellation policy — one that sits awkwardly against the FAQ, because the FAQ says there is no membership and nothing recurring to cancel while the Refund Policy describes a subscription charged the moment you finish the intake form, needing 72 hours' notice to stop, with no refund on cancellation.

One of the lowest disclosed GLP-1 starting prices in this round — from $99/mo semaglutide, $133/mo tirzepatide — with an explicit no-membership, no-hidden-fee claim, though the real ongoing rate at a working dose isn't confirmed.